Literature DB >> 2234220

Management of patients with brain metastases of unknown origin.

M Debevec1.   

Abstract

During the years 1973-1987, 75 patients were irradiated for brain metastases of unknown origin at the Institute of Oncology in Ljubljana. Of these, 35 (47%) were previously treated by surgery: Metastases were completely removed in 22 patients and partially in 7, whereas biopsy alone was performed in 6 patients. Based on the examinations carried out during radiation therapy and at the time of follow-up, the primary sites of tumor were established as follows: The lung in 40 patients, the breast in 2, melanoma in 2, and the esophagus, kidney, and parotid gland in one patient, respectively. Primary tumor could not be detected in 28 (37%) patients. Metastases were microscopically verified in 48 cases in which anaplastic carcinoma and adenocarcinoma were most frequent. All the patients were irradiated on a cobalt unit, generally with doses of 10 x 300 cGy in 2 weeks. Median survival of the 22 patients with total removal of brain metastases was 9.5 months, one-year survival being achieved in 41% of cases. In the remaining patients median survival was 3 months, whereas only 12% of the patients survived one year. The cause of death were most frequently, i.e. in 45 patients, brain metastases.

Entities:  

Mesh:

Year:  1990        PMID: 2234220

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  8 in total

1.  A study of patients with brain metastases as the initial manifestation of their systemic cancer in a Chinese population.

Authors:  Jia Jin; Xinli Zhou; Xiaohua Liang; Ruofan Huang; Zhaohui Chu; Jingwei Jiang; Qiong Zhan
Journal:  J Neurooncol       Date:  2010-10-27       Impact factor: 4.130

2.  Cerebral metastases as first symptom of cancer: a clinico-pathologic study.

Authors:  M T Giordana; S Cordera; A Boghi
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

3.  Determination of lung as the primary site of cerebral metastatic adenocarcinomas using monoclonal antibody to thyroid transcription factor-1.

Authors:  R J Bohinski; P A Bejarano; G Balko; R E Warnick; J A Whitsett
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

4.  Brain metastases in patients with cancer of unknown primary.

Authors:  Susanne Bartelt; Johannes Lutterbach
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

5.  Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated?

Authors:  M van de Pol; V C van Aalst; J T Wilmink; A Twijnstra
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

6.  Optimal Treatment Decision for Brain Metastases of Unknown Primary Origin: The Role and Timing of Radiosurgery.

Authors:  Hyun Jin Han; Won Seok Chang; Hyun Ho Jung; Yong Gou Park; Hae Yu Kim; Jong Hee Chang
Journal:  Brain Tumor Res Treat       Date:  2016-10-31

7.  CSF-ctDNA SMSEQ Analysis to Tailor the Treatment of a Patient with Brain Metastases: A Case Report.

Authors:  Wen-Tsung Huang; Na-Mi Lu; Wen-Yuan Hsu; Shih-En Chang; Alex Atkins; Rui Mei; Manana Javey
Journal:  Case Rep Oncol       Date:  2018-02-01

8.  Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center.

Authors:  L M Füreder; G Widhalm; B Gatterbauer; K Dieckmann; J A Hainfellner; R Bartsch; C C Zielinski; M Preusser; A S Berghoff
Journal:  Clin Exp Metastasis       Date:  2018-11-12       Impact factor: 5.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.